Steven A Buck
Overview
Explore the profile of Steven A Buck including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
506
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Carter J, Su Y, Al-Antary E, Zhao J, Qiao X, Wang G, et al.
J Exp Clin Cancer Res
. 2025 Jan;
44(1):10.
PMID: 39780285
Background: Venetoclax + azacitidine is a frontline treatment for older adult acute myeloid leukemia (AML) patients and a salvage therapy for relapsed/refractory patients who have been treated with intensive chemotherapy....
2.
Taub J, Buck S, Xavier A, Edwards H, Matherly L, Ge Y
Pediatr Blood Cancer
. 2024 Aug;
71(11):e31247.
PMID: 39120434
An attractive flower from the island of Madagascar has in part saved the lives of thousands of children with acute lymphoblastic leukemia (ALL). Random mutations and alterations to the genome...
3.
Su Y, Carter J, Li X, Fukuda Y, Gray A, Lynch J, et al.
Cancer Res
. 2024 Jan;
84(7):1084-1100.
PMID: 38266099
Significance: In AML cells, ONC213 suppresses αKGDH, which induces a unique mitochondrial stress response, and reduces MCL1 to decrease oxidative phosphorylation and elicit potent antileukemia activity. See related commentary by...
4.
Hurrish K, Su Y, Patel S, Ramage C, Zhao J, Temby B, et al.
Biochem Pharmacol
. 2023 Dec;
220:115981.
PMID: 38081370
Venetoclax (VEN), in combination with low dose cytarabine (AraC) or a hypomethylating agent, is FDA approved to treat acute myeloid leukemia (AML) in patients who are over the age of...
5.
Hurrish K, Su Y, Patel S, Ramage C, Carter J, Edwards H, et al.
Res Sq
. 2023 May;
PMID: 37162954
Venetoclax (VEN), in combination with low dose cytarabine (AraC) or a hypomethylating agent, is FDA approved to treat acute myeloid leukemia (AML) in patients who are over the age of...
6.
Luedtke D, Su Y, Ma J, Li X, Buck S, Edwards H, et al.
Signal Transduct Target Ther
. 2020 Apr;
5(1):17.
PMID: 32296028
Venetoclax, an FDA-approved Bcl-2 selective inhibitor for the treatment of chronic lymphocytic leukemia and acute myeloid leukemia (AML), is tolerated well in elderly patients with AML and has good overall...
7.
Luckinbill L, Arking R, Clare M, Cirocco W, Buck S
Evolution
. 2017 May;
38(5):996-1003.
PMID: 28555795
No abstract available.
8.
Sidhu A, Callaghan M, Gadgeel M, Buck S, Fribley A, Savasan S
J Pediatr Hematol Oncol
. 2017 Mar;
39(3):e163-e166.
PMID: 28333839
Autoimmune response targeting the hematopoietic stem cells highlights the current understanding of acquired aplastic anemia (AAA) pathogenesis. Upregulation of the unfolded protein response is the cell's rejoinder to a variety...
9.
Jesudas R, Buck S, Savasan S
Pediatr Blood Cancer
. 2016 Sep;
64(3).
PMID: 27682159
No abstract available.
10.
Hanmod S, Wang G, Edwards H, Buck S, Ge Y, Taub J, et al.
Pediatr Blood Cancer
. 2014 Oct;
62(1):52-9.
PMID: 25308916
Background: Despite advances in treatment regimens, patients with high-risk neuroblastoma have long-term survival rates of < 40%. Wee1 inhibition in combination with CHK1 inhibition has shown promising results in neuroblastoma...